United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - naloxegol oxalate (unii: 65i14tnm33) (naloxegol - unii:44t7335bke) - naloxegol 12.5 mg - movantik® is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. movantik is contraindicated in: risk summary limited available data with movantik use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. movantik may precipitate opioid withdrawal in the pregnant women and the fetus (see clinical considerations) . in animal development studies, no effects on embryo-fetal development were observed following administration of naloxegol in pregnant rats during the period of organogenesis at doses up to 1452 times the human auc (area under the plasma concentration-time curve) at the maximum recommended human dose. no effects on embryo-fetal development were observed following administration of naloxegol in pregnant rabbits during the period of organogenesis at

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ego pharmaceutical proprietary limited - melaleuca oil - liquid - melaleuca oil oil-plant extract active 50.0 mg/g - household insecticide - pest control - personal use - fly | mosquito | sand fly (biting midge) | adult mosquitoes

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ego pharmaceutical proprietary limited - melaleuca oil - liquid - melaleuca oil oil-plant extract active 50.0 mg/g - household insecticide - pest control - personal use - fly | mosquito | sand fly (biting midge) | adult mosquitoes

United States - English - NLM (National Library of Medicine)

quality care products, llc - naloxegol oxalate (unii: 65i14tnm33) (naloxegol - unii:44t7335bke) - naloxegol 25 mg - movantik® (naloxegol) is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain. movantik is contraindicated in: pregnancy category c risk summary there are no adequate and well-controlled studies with movantik in pregnant women. the use of movantik during pregnancy may precipitate opioid withdrawal in a fetus due to the immature fetal blood brain barrier. no effects on embryo-fetal development were observed following administration of naloxegol in pregnant rats during the period of organogenesis at doses up to 1452 times the human auc (area under the plasma concentration-time curve) at the maximum recommended human dose. no effects on embryo-fetal development were observed following administration of naloxegol in pregnant rabbits during the period of organogenesis at doses up to 409 times the human auc at the maximum recommended human dose. movantik should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Ireland - English - HPRA (Health Products Regulatory Authority)

ego pharmaceuticals (uk) limited - eucalyptus globulus - cutaneous solution - 11.0 %w/w

Ireland - English - HPRA (Health Products Regulatory Authority)

ego pharmaceuticals (uk) limited - eucalyptus globulus - cutaneous solution - 11.0 %w/w

Ireland - English - HPRA (Health Products Regulatory Authority)

ego pharmaceuticals (uk) limited - ichthammol zinc oxide - ointment - 1.0/ 15.0 %w/w

Ireland - English - HPRA (Health Products Regulatory Authority)

ego pharmaceuticals (uk) limited - coal tar - cutaneous solution - 2.30 %w/w

Ireland - English - HPRA (Health Products Regulatory Authority)

ego pharmaceuticals (uk) limited - glycerol liquid paraffin light white soft paraffin - cream - 10/10/5%w/ %v/v